A Single-Dose Intranasal Combination Panebolavirus Vaccine
The Journal of Infectious Diseases · 2023
DOI: 10.1093/infdis/jiad266 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Delphine C Malherbe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA. Hauptthemen laut MEDLINE: Ebola Vaccines, Hemorrhagic Fever, Ebola, Ebolavirus. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
Ebolaviruses Ebola (EBOV), Sudan (SUDV), and Bundibugyo (BDBV) cause severe human disease, which may be accompanied by hemorrhagic syndrome, with high case fatality rates. Monovalent vaccines do not offer cross-protection against these viruses whose endemic areas overlap. Therefore, development of a panebolavirus vaccine is a priority. As a vaccine vector, human parainfluenza virus type 3 (HPIV3) has the advantages of needle-free administration and induction of both systemic and local mucosal antibody responses in the respiratory tract.
Methods
To minimize the antivector immunity, genes encoding the HPIV3 envelope proteins F and HN were removed from the vaccine constructs, resulting in expression of only the ebolavirus envelope protein—glycoprotein. These second-generation vaccine constructs were used to develop a combination vaccine against EBOV, SUDV, and BDBV.
Results
A single intranasal vaccination of guinea pigs or ferrets with the trivalent combination vaccine elicited humoral responses to each of the targeted ebolaviruses, including binding and neutralizing antibodies, as well as Fc-mediated effector functions. This vaccine protected animals from death and disease caused by lethal challenges with EBOV, SUDV, or BDBV.
Conclusions
The combination vaccine elicited protection that was comparable to that induced by the monovalent vaccines, thus demonstrating the value of this combination trivalent vaccine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
- Galveston National Laboratory, Galveston, Texas, USA.
- Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
ORCID-Profile: Alexander Bukreyev
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
Zitieren
APA
Malherbe, D. C., Kimble, J. B., Atyeo, C., Fischinger, S., Meyer, M., Cody, S. G., Hyde, M., Alter, G., & Bukreyev, A. (2023). A Single-Dose Intranasal Combination Panebolavirus Vaccine. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad266
Vancouver
Malherbe DC, Kimble JB, Atyeo C, Fischinger S, Meyer M, Cody SG, et al. A Single-Dose Intranasal Combination Panebolavirus Vaccine. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad266
BibTeX
@article{Malherbe2023,
author = {Malherbe, Delphine C and Kimble, J Brian and Atyeo, Caroline and Fischinger, Stephanie and Meyer, Michelle and Cody, S Gabrielle and Hyde, Matthew and Alter, Galit and Bukreyev, Alexander},
title = {A Single-Dose Intranasal Combination Panebolavirus Vaccine},
journal = {The Journal of Infectious Diseases},
year = {2023},
doi = {10.1093/infdis/jiad266}
}
EUVIMED